Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Outlook Therapeutics (OTLK) over the last 8 years, with Q4 2025 value amounting to $49.1 million.

  • Outlook Therapeutics' Total Current Liabilities rose 169.69% to $49.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $49.1 million, marking a year-over-year increase of 169.69%. This contributed to the annual value of $45.8 million for FY2025, which is N/A changed from last year.
  • Outlook Therapeutics' Total Current Liabilities amounted to $49.1 million in Q4 2025, which was up 169.69% from $45.8 million recorded in Q3 2025.
  • Over the past 5 years, Outlook Therapeutics' Total Current Liabilities peaked at $49.1 million during Q4 2025, and registered a low of $24.8 million during Q1 2025.